http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111500582-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8bb503bbe892f3a17fc6ac9b626a3dda |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-16 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-115 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-111 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7088 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-115 |
| filingDate | 2019-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-111500582-A |
| titleOfInvention | Development of a metastatic specific nucleic acid aptamer AIA2-targeted drug for prostate cancer |
| abstract | The invention belongs to the application category of new medical technology, that is, firstly establishing a subgroup of highly invasive prostate cancer cells and a subgroup of low invasive prostate cancer cells, performing positive and negative screening on a nucleic acid aptamer library, and obtaining cells that inhibit the metastasis of prostate cancer cells. targeted compounds. On this basis, the present invention further detects and verifies the screened nucleic acid aptamers, and it is confirmed that AIA2 has the ability to inhibit tumor invasion and metastasis in vivo and in vitro; the effect of aptamer AIA2 on tumor cell survival and growth is confirmed . Nucleic acid aptamers have the advantages of low immunogenicity, can be obtained by chemical synthesis methods, and stable compounds. They have become new drugs that can replace antibodies for immunotherapy of diseases. Further elucidation of the mechanism of action of AIA2 makes it a promising new targeted drug for the prevention and treatment of prostate cancer metastasis. |
| priorityDate | 2019-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 24.